Currently, studies on CSF TDP-43 in ALS are highly heterogenous in terms of sample size, the analytical assay used for measuring the biomarker, and inclusion and exclusion criteria for patients and, especially, for controls. This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.